JP Morgan Reinstates Overweight on Denali Therapeutics, Announces $29 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 56.7%

Neg 0% Neu 56.7% Pos 0%

JP Morgan analyst Jessica Fye reinstates Denali Therapeutics (NASDAQ:DNLI) with a Overweight and announces $29 price target.